Alnylam Pharmaceuticals (NASDAQ:ALNY) Receives Buy Rating from Chardan Capital

Chardan Capital reissued their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research report sent to investors on Wednesday,Benzinga reports. They currently have a $300.00 price objective on the biopharmaceutical company’s stock.

ALNY has been the topic of a number of other reports. Barclays lifted their price target on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a report on Friday, November 1st. Wolfe Research downgraded Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a report on Tuesday, November 12th. HC Wainwright lifted their price target on Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the company a “buy” rating in a report on Monday, February 24th. StockNews.com downgraded Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 9th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a report on Tuesday, February 11th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $304.26.

Alnylam Pharmaceuticals Trading Up 4.1 %

Shares of NASDAQ ALNY opened at $246.75 on Wednesday. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The business has a fifty day simple moving average of $254.30 and a two-hundred day simple moving average of $262.42. The firm has a market cap of $31.94 billion, a PE ratio of -113.71 and a beta of 0.35. Alnylam Pharmaceuticals has a twelve month low of $141.98 and a twelve month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). Analysts expect that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CFO Jeffrey V. Poulton sold 967 shares of the business’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $246,749.39. Following the sale, the chief financial officer now owns 32,786 shares in the company, valued at approximately $8,366,003.62. The trade was a 2.86 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Yvonne Greenstreet sold 1,213 shares of the business’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $309,521.21. Following the sale, the chief executive officer now owns 81,526 shares in the company, valued at approximately $20,802,989.42. The trade was a 1.47 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 72,986 shares of company stock worth $20,397,849. 1.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of ALNY. Allspring Global Investments Holdings LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 62.2% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 420 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 161 shares during the period. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 56.2% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 6,454 shares of the biopharmaceutical company’s stock valued at $1,775,000 after buying an additional 2,323 shares during the period. Nisa Investment Advisors LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 41.4% in the 3rd quarter. Nisa Investment Advisors LLC now owns 11,528 shares of the biopharmaceutical company’s stock valued at $3,171,000 after buying an additional 3,373 shares during the period. Pallas Capital Advisors LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 61.8% in the 3rd quarter. Pallas Capital Advisors LLC now owns 3,321 shares of the biopharmaceutical company’s stock valued at $975,000 after buying an additional 1,269 shares during the period. Finally, New York State Teachers Retirement System acquired a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at about $1,453,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.